Literature DB >> 2294578

Cranial postoperative site: assessment with contrast-enhanced MR imaging.

A D Elster1, D A DiPersio.   

Abstract

To define duration and patterns of postoperative contrast material enhancement, the authors evaluated magnetic resonance (MR) images obtained with gadolinium diethylenetriaminepentaacetic acid (DTPA) in 46 patients who had undergone major intracranial surgery. Intervals between surgery and MR imaging ranged from 1 day to 40 years (median, 1.3 years). Moderate or marked brain and dural enhancement was noted in nearly every patient imaged within 3 months of surgery, but all brain enhancement was gone by 1 year. Abnormal dural enhancement was noted in every patient imaged within 1 year of surgery and in approximately 50% at 1-2 years afterward. One patient had persistent mild enhancement of the dura 40 years after surgery. MR images revealed enhancement in several sites not frequently recognized on computed tomographic (CT) scans. Brain and meningeal enhancement with Gd-DTPA at cranial operative sites was more extensive and persisted much longer than is commonly seen on contrast-enhanced CT scans. Enhancement of the brain or pia mater does not normally last beyond 1 year, but dural enhancement may persist for decades.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2294578     DOI: 10.1148/radiology.174.1.2294578

Source DB:  PubMed          Journal:  Radiology        ISSN: 0033-8419            Impact factor:   11.105


  18 in total

1.  Surgically induced intracranial contrast enhancement: potential source of diagnostic error in intraoperative MR imaging.

Authors:  M Knauth; N Aras; C R Wirtz; A Dörfler; T Engelhorn; K Sartor
Journal:  AJNR Am J Neuroradiol       Date:  1999-09       Impact factor: 3.825

Review 2.  Pachymeningeal enhancement-a comprehensive review of literature.

Authors:  Joyce Antony; Craig Hacking; Rosalind L Jeffree
Journal:  Neurosurg Rev       Date:  2015-08-13       Impact factor: 3.042

3.  [Intracerebral tumors in adulthood. 1: Intra-axial tumors].

Authors:  I Grunwald; T Struffert; H Ghazzawie; V Möller; W Reith; V Höller
Journal:  Radiologe       Date:  2002-07       Impact factor: 0.635

4.  Residual and recurrent acoustic neuroma in hearing preservation procedures: neuroradiologic and surgical findings.

Authors:  A Mazzoni; V Calabrese; L Moschini
Journal:  Skull Base Surg       Date:  1996

5.  Evaluation of early response to SU101 target-based therapy in patients with recurrent supratentorial malignant gliomas using FDG PET and Gd-DTPA MRI.

Authors:  A G Vlassenko; B Thiessen; B J Beattie; M G Malkin; R G Blasberg
Journal:  J Neurooncol       Date:  2000       Impact factor: 4.130

6.  Recurrent malignant glioma: detection with 131I labeled monoclonal antibody G-22, positron emission tomography and magnetic resonance imaging.

Authors:  M Oshima; J Yoshida; T Wakabayashi; K Ito; M Tadokoro; T Kato; S Sakuma
Journal:  Ann Nucl Med       Date:  1993-05       Impact factor: 2.668

7.  Dynamic Contrast-Enhanced MRI in Patients with Brain Metastases Undergoing Laser Interstitial Thermal Therapy: A Pilot Study.

Authors:  J I Traylor; D C A Bastos; D Fuentes; M Muir; R Patel; V A Kumar; R J Stafford; G Rao; S S Prabhu
Journal:  AJNR Am J Neuroradiol       Date:  2019-08-01       Impact factor: 3.825

8.  Spurious leptomeningeal enhancement on immediate post-operative MRI for paediatric brain tumours.

Authors:  Elysa Widjaja; Daniel J A Connolly; Sylvia Gatscher; John McMullen; Paul D Griffiths
Journal:  Pediatr Radiol       Date:  2004-11-13

9.  Time-dependent scar enhancement in magnetic resonance imaging of the postoperative lumbar spine.

Authors:  M F Glickstein; S K Sussman
Journal:  Skeletal Radiol       Date:  1991       Impact factor: 2.199

10.  Baseline and follow-up MRI of the internal auditory canal after suboccipital resection of acoustic schwannoma: appearances and clinical correlations.

Authors:  M Smith; M Castillo; J Campbell; H Pillsbury; T Walters
Journal:  Neuroradiology       Date:  1995-05       Impact factor: 2.804

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.